Piramal’s Healthcare vertical has announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, ...

The incorporation of Synaffix's GlycoConnect™, HydraSpace® and toxSYN® ADC technologies is intended to further improve the safety and efficacy of Big Hat’s next-gen ADC. Peter van de Sande, Head of ...